We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.65%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.58B
AUM Growth
-$133M
Cap. Flow
-$75.4M
Cap. Flow %
-1.64%
Top 10 Hldgs %
23.53%
Holding
172
New
18
Increased
60
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$102M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$50.7M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$48.4M
4
CGEM icon
Cullinan Oncology
CGEM
+$43.7M
5
AZN icon
AstraZeneca
AZN
+$32.7M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$58.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
UNH icon
UnitedHealth
UNH
+$45M
4
CNC icon
Centene
CNC
+$43.8M
5
IMVT icon
Immunovant
IMVT
+$41.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Consumer Staples 1.75%
3 Industrials 0.62%
4 Financials 0.12%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STTK icon
101
Shattuck Labs
STTK
$682M
$11.4M 0.25%
388,499
-100,501
-21% -$4.22M
CNMD icon
102
CONMED
CNMD
$1.48B
$11.1M 0.24%
85,085
+7,085
+9% +$853K
TARA icon
103
Protara Therapeutics
TARA
$231M
$10.9M 0.24%
689,942
+46,742
+7% +$867K
KYNB
104
Kyntra Bio
KYNB
$28.2M
$10.9M 0.24%
12,507
+132
+1% +$141K
TBIO
105
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$10.7M 0.23%
649,900
+6,400
+1% +$146K
NGM
106
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$10.6M 0.23%
364,800
+4,300
+1% +$120K
RXDX
107
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$10.5M 0.23%
+574,858
New +$11.9M
CGEN icon
108
Compugen
CGEN
$221M
$10.5M 0.23%
1,219,488
+85,888
+8% +$952K
KDNY
109
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$10.5M 0.23%
673,049
+4,200
+0.6% +$68.5K
XENE icon
110
Xenon Pharmaceuticals
XENE
$6.21B
$10.2M 0.22%
572,500
+57,500
+11% +$975K
KNTE
111
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$10.2M 0.22%
326,386
+1,700
+0.5% +$59.2K
FUSN
112
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$10.2M 0.22%
948,327
– –
AUPH icon
113
Aurinia Pharmaceuticals
AUPH
$2.06B
$10.1M 0.22%
781,569
+7,900
+1% +$115K
FOLD
114
DELISTED
Amicus Therapeutics
FOLD
$10M 0.22%
1,012,506
-16,494
-2% -$255K
OHPAU
115
DELISTED
Orion Acquisition Corp. Unit
OHPAU
$10M 0.22%
+1,000,000
New +$10M
DSGN icon
116
Design Therapeutics
DSGN
$897M
$9.79M 0.21%
+327,250
New +$11M
NRIX icon
117
Nurix Therapeutics
NRIX
$2.69B
$9.67M 0.21%
310,950
+53,700
+21% +$2.03M
LEGN icon
118
Legend Biotech
LEGN
$4B
$9.07M 0.2%
312,618
+3,200
+1% +$87.3K
RLAY icon
119
Relay Therapeutics
RLAY
$4.37B
$8.72M 0.19%
252,127
-159,873
-39% -$6.94M
ADAP
120
DELISTED
Adaptimmune Therapeutics
ADAP
$8.2M 0.18%
1,545,000
– –
WST icon
121
West Pharmaceutical
WST
$24.8B
$8.03M 0.18%
28,500
– –
BCEL
122
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6.96M 0.15%
453,930
+2,700
+0.6% +$43.9K
CHMA
123
DELISTED
Chiasma, Inc. Common Stock
CHMA
$6.81M 0.15%
2,174,583
+38,069
+2% +$146K
TRIL
124
DELISTED
Trillium Therapeutics Inc.
TRIL
$6.67M 0.15%
620,800
+2,300
+0.4% +$28.4K
TLPH icon
125
Talphera
TLPH
$73.2M
$6.43M 0.14%
189,273
+150
+0.1% +$5.95K
3 4
5
6 7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rock Springs Capital Management held 172 positions worth $4.58B, down 2.8% from $4.72B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q1 2021 filing shows 18 new, 60 increased, 32 reduced and 21 closed positions. Its largest new stake was Immunocore: 2,292,285 shares worth $97.6M. The largest sale was Neurocrine Biosciences, an estimated $58.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2021 buy was Immunocore: 2,292,285 shares worth $97.6M.
  • Rock Springs Capital Management added most to Five Prime Therapeutics, Inc. in Q1 2021, an estimated $48.4M increase.
  • Rock Springs Capital Management's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $58.7M.
  • Rock Springs Capital Management fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $47.9M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.58B portfolio in Q1 2021.
  • Rock Springs Capital Management opened 18 new positions and closed 21 in Q1 2021.
  • Rock Springs Capital Management's portfolio value fell 2.8% quarter-over-quarter to $4.58B.

Based on Rock Springs Capital Management's 13F filing for Q1 2021, filed 17 May 2021.